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Edited by John DenuThe mitogen-responsive, ETS-domain transcription factor
ELK-1 stimulates the expression of immediate early genes at
the onset of the cell cycle and participates in early develop-
mental programming. ELK-1 is subject to multiple levels of
posttranslational control, including phosphorylation,
SUMOylation, and ubiquitination. Recently, removal of mon-
oubiquitin from the ELK-1 ETS domain by the Ubiquitin
Specific Protease USP17 was shown to augment ELK-1 tran-
scriptional activity and promote cell proliferation. Here we
have used coimmunoprecipitation experiments, protein turn-
over and ubiquitination assays, RNA-interference and gene
expression analyses to examine the possibility that USP17 acts
antagonistically with the F-box protein FBXO25, an E3 ubiq-
uitin ligase previously shown to promote ELK-1 ubiquitination
and degradation. Our data confirm that FBXO25 and ELK-1
interact in HEK293T cells and that FBXO25 is active toward
Hand1 and HAX1, two of its other candidate substrates.
However, our data indicate that FBXO25 neither promotes
ubiquitination of ELK-1 nor impacts on its transcriptional ac-
tivity and suggest that an E3 ubiquitin ligase other than
FBXO25 regulates ELK-1 ubiquitination and function.
In multicellular organisms, the importance of restricting cell
proliferation is such that mitogen-responsive transcription
factors are subject tomultiple levels of control. For example, the
ETS transcription factor ELK-1 is phosphorylated by extracel-
lular signal-regulated kinases (ERKs) in response to growth
factor signaling and transiently activated to initiate a gene
expression program for cell cycle onset and proliferation (1–3).
Activation of a key subset of target genes is dependent on
recruitment of ELK-1 to their promoters in a ternary complex
with serum response factor (SRF) (4, 5). Conversely, ELK-1
binding has also been correlated with polycomb repressor
complexes in chromatin (6, 7) and in this context appears able to
repress developmental gene expression. Furthermore, ELK-1
can compete with myocardin-related transcription factors
(MRTFs) for binding to SRF at muscle-specific gene promoters
(8–10). Notably, in amphibian and primitive chordate embryos,This article contains supporting information.
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include the precocious appearance of mesoderm, suggesting
that ELK-1 participates in the suppression of mesoderm for-
mation (11, 12). Thus ELK-1 contributes to the coordination of
cell proliferation with tissue specification and serves as a para-
digm for mitogen-responsive transcription factors. Under-
standing how ELK-1 is regulated is therefore an important goal
in cancer and developmental biology.
Aside from phosphorylation, other signaling axes that
impinge on ELK-1 within the ERK/ELK-1/SRF regulatory nexus
are SUMOylation, which represses ELK-1 transcriptional ac-
tivity (6, 7), and the ubiquitin proteasome system (UPS), which
regulates ELK-1 turnover (13). Moreover, ELK-1 is reversibly
monoubiquitinated, which interferes with its activity, and the
cell cycle regulated ubiquitin-specific protease USP17 is able to
deubiquitinate and reactivate ELK-1 (14–16). Depletion of
USP17 slowed cell proliferation but expression of an ELK-1
mutant refractory to monoubiquitination partially rescued the
proliferation defect. USP17 knockdown also caused heteroge-
neous differentiation of murine ES cells (17). Thus, reversible
ELK-1 monoubiquitination may play a pivotal role in coordi-
nating cell proliferation during early development, and it follows
that the E3 ubiquitin ligase responsible for monoubiquitination
of ELK-1 is central to this regulatory mechanism.
FBXO25 is one of a number of F-box proteins that serve as
substrate recognition subunits for SKP1/Cullin1/F-box protein
(SCF) complexes, a subfamily of E3 ubiquitin ligases (18). It is
closely related to Atrogin-1/FBXO32, an E3 ligase expressed in
striated muscle and associated with muscle atrophy (19).
Whereas FBXO32 expression is muscle-specific, FBXO25 is
expressed in neuronal cells and the human FBXO25 gene is
disrupted in a patient with intellectual disability and epileptic
seizures (20). FBXO25 was recently identified as an E3 ubiquitin
ligase that promotes the ubiquitination and degradation of ELK-
1 (21, 22). We therefore examined whether FBXO25 could also
catalyze the monoubiquitination of ELK-1 and thereby operate
in opposition to USP17. Although we confirmed that FBXO25
can interact with ELK-1 in cells, an antagonistic relationship
between FBXO25 and USP17 toward ELK-1 was not apparent.
Indeed, although FBXO25 activitywas confirmedwith twoother
candidate substrates, we were unable to detect ubiquitination of
ELK-1 or modulation of its function by FBXO25, as previously
reported (22).J. Biol. Chem. (2021) 296 100214 1
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FBXO25 pseudo-substrate ELK-1Results and discussion
ELK-1 is a substrate for both mono- and polyubiquitination,
and we recently showed that USP17 removes monoubiquitin
(mUBQ) from ELK-1 (13, 14). USP17 also removes poly-
ubiquitin chains (pUBQ) from ELK-1 (see below), implying an
antagonistic relationship between USP17 and FBXO25, an E3
ubiquitin ligase recently reported to catalyze poly-
ubiquitination of ELK-1 (22).
ELK-1 was first identified as a potential substrate for
FBXO25 through in vitro interactions (21). Using a V5/His-
tagged version of FBXO25, we could detect its interaction
with ELK-1 in HEK293T cells [Fig. 1A]. FBXO25 with an
S244L mutation in the F-box thought to impair interactions
with SKP1 also interacted with ELK-1 (20). We used ELK-1Figure 1. FBXO25 can interact with ELK-1 via cryptic degron sequences.
FBXO25 or FBXO25-S244L, as indicated. ELK-1 was recovered from lysates
preimmune control), precipitated proteins were resolved by SDS-PAGE and i
detected with αV5 antibody. The experiment was performed three times w
mutants used in Co-IP experiments showing domain structure of ELK-1, con
regulated inhibitory domain, mitogen-activated protein kinase (MAPK) doc
from the deletion mutants are indicated below. C, HEK293T cells were transf
mutants indicated. Co-IP experiments were performed as described in part
ELK-1 deletion mutant ratio in relation to FBXO25/ELK-1 ratio. The exp
transfected with FBXO25 and ELK-1 or ELK-1 deletion mutants Δ167 to 1
described in part (A). Panels on left and right are from the same blots; irr
second panels represent the FBXO25/ELK-1 deletion mutant ratio in relation
similar results.
2 J. Biol. Chem. (2021) 296 100214deletions to map the surface on ELK-1 required for interac-
tion with FBXO25. ELK-1 deletions Δ167 to 216 and Δ167 to
196 [see Fig. 2B] localize the interaction with FBXO25 to a
region encompassing a cryptic degron in ELK-1 that was
defined previously (13) [Fig. 1, C–D]. These results confirm
that ectopically expressed FBXO25 and ELK-1 interact in
cells (22).
Expression of FBXO25 in HEK293T cells was reported to
increase ELK-pUBQ levels (22). To determine if FBXO25
catalyzed monoubiquitination of ELK-1, we used immobilized
metal affinity chromatography (IMAC) to isolate his-tagged
UBQ-ELK-1 conjugates from denatured HEK293T cell ly-
sates. However, ectopic expression of V5-tagged FBXO25
(without His-tag) had no more effect on levels ofA, HEK293T cells were transfected with expression vectors for ELK-1 and
by immunoprecipitation (IP) with polyclonal αElkC antibody (P indicates
mmunoblotted with the antibodies indicated; FBXO25/FBXO25-S244L was
ith similar results. B, schematic representation of ELK-1 and its deletion
sisting of N-terminal ETS domain; SRF-interaction domain (B-box); SUMO-
king motif (D-box); C-terminal transactivation domain. Sequences absent
ected with expression vectors for FBXO25 and ELK-1 or the ELK-1 deletion
(A). Numbers between the first and second panels represent the FBXO25/
eriment was performed four times with similar results. D, cells were
96 or Δ187 to 216, as indicated. Co-IP experiments were performed as
elevant bands in between were cut out. Numbers between the first and
to FBXO25/ELK-1 ratio. The experiment was performed three times with
FBXO25 pseudo-substrate ELK-1monoubiquitinated ELK-1 (ELK-mUBQ) than the C terminus
of HSP70 interacting protein (CHIP), which we used as a
negative control [Fig. 2A]. Moreover, ubiquitination assays also
revealed no effect of FBXO25 (or CHIP) expression on levels
of polyubiquitinated ELK-1 (ELK-pUBQ) [Fig. 2B]. Since cell
lysis and IMAC were performed under denaturing conditions,
associations between ELK-1 and noncovalently bound pUBQ
chains are ruled out.
Ectopic expression of FBXO25 in HEK293T cells was re-
ported to reduce steady-state levels of ELK-1 and to increase
the rate of ELK-1 turnover (22). However, we observed that
steady-state levels of endogenous or ectopically expressed
ELK-1 were unaffected by FBXO25 expression [Fig. 2C].
Furthermore, cycloheximide chase experiments suggested that
FBXO25 expression only marginally affected the half-life of
ELK-1 [Fig. 2D].
We considered the possibility that the V5 epitope on the
C terminus of FBXO25 might interfere with its activity
toward ELK-1. We therefore produced N-terminal Myc-
tagged versions, corresponding to FBXO25 mRNA vari-
ants 1 and 2 (NM_183421 and NM_183420), as well as a
mutant version lacking the F-box domain (amino acids
228–266; ΔF) that cannot interact with SKP1 or other
components of the SCF1 complex. Consistent with the
results obtained using FBXO25-V5, no increase in ELK-
pUBQ was observed upon coexpression of Myc-FBXO25
in HEK293T cells, with or without treatment with
MG132 [Fig. 3, A–B].
To confirm the functional integrity of ectopically expressed
FBXO25, we turned to other potential client proteins. FBXO25
was reported to ubiquitinate several cardiac-specific tran-
scription factors including Hand1, a basic Helix-Loop-Helix
(bHLH) protein (23). Myc-FBXO25 expression significantly
increased levels of polyubiquitinated Hand1 in HEK293T cells
[Fig. 3, C–D]. We also assessed the activity of FBXO25 in HeLa
cells and found that its expression increased levels of poly-
ubiquitinated Hand1 but did not promote polyubiquitination
of ELK-1 [Fig. 3E] (see also Supplementary Information).
Diglycine remnant mapping of UBQ-Hand1 conjugates from
HEK293T cells using protein mass spectrometry confirmed
ubiquitination of Hand1 on lysine 163, which maps C terminal
to the bHLH domain [Fig. 3F] (see also Supplementary
Information).
FBXO25 has also been shown to target the HCLS1-
associated protein X-1 (HAX1) after apoptotic stress (24).
We found that Myc-FBXO25 expression in MEFs acceler-
ated the loss of HAX1 induced by etoposide, as previously
reported (24), whereas the ΔF-box mutant did not [Fig. 3,
G–H]. No corresponding change in the level of endoge-
nous ELK-1 was observed. On the basis of the results with
Hand1 and HAX-1, we conclude that ectopically expressed
FBXO25 is active in cells, although its activity appears to
be modest.Ectopic FBXO25 expression was previously shown to impair
ELK-1 target gene expression in HEK293T cells (22), and
conceivably, gene expression may be sensitive to even slight
changes in ELK-1 ubiquitination. However, in unstimulated
and mitogen-stimulated HEK293T cells, we found that mRNA
levels of ELK-1 target genes CFOS and EGR1 were unaffected
by FBXO25 expression [Fig. 4, A–B]. In contrast, expression of
USP17, but not a catalytically inactive USP17 mutant or USP7,
had a significant impact on ELK-1 target gene expression,
consistent with its ability to deubiquitinate ELK-1 [Fig. 4,
C–D] (14, 15).
HEK293T cells were reported to express endogenous
FBXO25, for which several isoforms exist (25). We first
confirmed expression of FBXO25 isoforms (3% of ectopic
FBXO25 expression) [Fig. 5A; lane 7]. To see if this low
endogenous FBXO25 expression accounted for ELK-1 poly-
ubiquitination observed in HEK293T cells, we used two
shRNAs to target FBXO25. Although each shRNA decreased
FBXO25 expression in HEK293T cells [Fig. 5B], neither
diminished polyubiquitination of ELK-1 [Fig. 5C]. As with its
overexpression, depletion of FBXO25 had no impact on CFOS
and EGR1 mRNA levels [Fig. 5D]. In contrast, shRNA-
mediated depletion of USP17 caused an increase in the levels
of ubiquitinated ELK-1 [Fig. 5E] and a significant decrease in
CFOS and EGR1 mRNA levels [Fig. 5F]. These results confirm
that altering the ubiquitination status of ELK-1 affects the
expression of its target genes (14).
In summary, FBXO25 and USP17 appear unlikely to act
antagonistically toward ELK-1. Although ectopically expressed
FBXO25 interacted with ELK-1 and the interaction mapped to
a previously defined cryptic degron in ELK-1 (13), it did not
increase ELK-mUBQ nor ELK-pUBQ levels in HEK293T or
HeLa cells, nor did it affect ELK-1 turnover. Conversely,
FBXO25 depletion did not decrease ELK-pUBQ levels in
HEK293T cells. Moreover, neither expression nor depletion of
FBXO25 altered ELK-1 target gene expression. We confirmed
that FBXO25 was active toward Hand1 and HAX1, two
independently defined FBXO25 substrates (23, 24), and
showed that levels of ELK-1 ubiquitination and target gene
expression can be modulated in synchrony by varying the
ubiquitin profile of ELK-1 with USP17.
Our findings provide further evidence that ubiquitination
modulates ELK-1 activity but do not support the notion that
FBXO25 is the principal ELK-1 E3 ubiquitin ligase. Possible
reasons why our findings differ from those reported previ-
ously for FBXO25 (22) include: the likely divergence of
HEK293T cells cultured in separate labs over time, the
different FBXO25 expression constructs employed, and the
alternative experimental conditions used for ubiquitination
assays. Our data also indicate that methods to detect in-
teractions between E3 ubiquitin ligases and prospective
clients, either in vitro or in cells, should not be considered a
reliable basis for inferring productive, functionalJ. Biol. Chem. (2021) 296 100214 3
Figure 2. FBXO25 has no effect on ELK-1 ubiquitination or stability. A, HEK293T cells were cotransfected with expression plasmids for His-Tyg-Ubiquitin,
HA-ELK-1, FBXO25-V5, CHIP-V5, or empty vector as indicated. Whole-cell lysates were prepared and 10% was used as input control; from the remainder, His-
Tyg-Ubiquitin conjugates were purified by IMAC under denaturing conditions. IMAC and lysate fractions were analyzed by SDS-PAGE and immunoblotting
using the antibodies indicated. NB, the Tyg epitope is EVHTNQDPLD. Arrowhead indicates ELK-mUBQ. Higher MW species are a mixture of di/triubiqui-
tinated and multiply monoubiquitinated ELK-1 (14, 15). The experiment was performed twice with the same result. B, HEK293T cells were cotransfected with
expression plasmids for ELK-1-His, HA-UBQ FBXO25-V5, CHIP-V5, or empty vector as indicated. Whole-cell lysates were prepared and 10% was used as input
control; from the remainder, His-tagged ELK-1 was purified by IMAC under denaturing conditions. IMAC and lysate fractions were analyzed by SDS-PAGE
and immunoblotting using the antibodies indicated. The experiment was performed twice with the same result. C, Upper panel, an expression plasmid for
HA-ELK-1 was transfected alone (1 μg) or together with increasing amounts (0.2, 0.5, 1, 2, 3 μg) of FBXO25 plasmid, supplemented with empty vector for
constant DNA input, into HEK293T cells. Cells were lysed and equal amounts of protein were assayed by SDS-PAGE and immunoblotting. Levels of HA-ELK-1
or FBXO25-V5 were detected using αHA and αV5 antibodies, respectively. HSP90 was used as loading control. Lower panel, increasing amounts (0.2, 0.5, 1, 2,
3 μg) of FBXO25 plasmid, supplemented with empty vector for constant DNA input, were transfected into HEK293T cells. Cells were lysed and equal
amounts of protein were assayed by SDS-PAGE and immunoblotting. The levels of endogenous ELK-1 (lower band; asterisk indicates nonspecific signal) or
overexpressed FBXO25-V5 were detected using H160 and αV5 antibodies respectively. HSP90 was used as loading control. Lower panel shows densitometric
quantification of the results, in which levels of ELK-1 were normalized to HSP90. For all experiments n = 3. D, HEK293T were transfected with expression
FBXO25 pseudo-substrate ELK-1
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FBXO25 pseudo-substrate ELK-1relationships. We conclude that the E3 ubiquitin ligase with
an important role in limiting ELK-1 activity during cell
proliferation and vertebrate development remains to be
identified.Experimental procedures
Cell culture and extract preparation
HEK293T and HeLa cells were grown in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 10%
fetal calf serum (FCS), 2 mM L-glutamine, 100 U ml−1 peni-
cillin, and 100 μg ml−1 streptomycin. Murine embryonic fi-
broblasts (MEFs) were cultured in DMEM high glucose,
supplemented with 10% FCS, 100 U ml−1 penicillin, and
100 μg ml−1 streptomycin. Whole-cell lysates were prepared in
a modified RIPA buffer containing 50 mM Tris HCl pH 7.5,
150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS.
Plasmids and DNA transfection
Plasmids and sources are listed in the Supplementary
Information. All constructs were verified by DNA
sequencing. HEK293T cells at a density of 3 × 106 cells per
10 cm dish were transfected with a total of 10 μg DNA via
calcium phosphate/DNA coprecipitation. HeLa cells were
transfected with TransIT-LT1 reagent (Mirus Bio); MEFs were
transfected using the K2 transfection system (Biontex).
Coimmunoprecipitations
Experiments were performed essentially as described pre-
viously (26). Cells were lysed in co-IP buffer containing 25 mM
Tris HCl pH 7.5, 150 mM KCl, 10 mM NaF, 1 mM Na3VO4,
1% NP-40, supplemented with mammalian protease and
phosphatase inhibitor cocktails (Sigma Aldrich) for 1 h at 4 C,
and cleared by centrifugation. Lysates were normalized for
protein concentration, precleared with protein G sepharose
beads and immune complexes were allowed to form over night
at 4 C on a rotating wheel. Antibodies used are listed in
Supplementary Information. Immune complexes were
collected on protein G Sepharose beads by centrifugation,
washed five times in co-IP buffer, and released by boiling in
SDS gel-loading buffer.
Ubiquitination assays
Cells were lysed in buffer containing 6 M Guanidinium-HCl
and protein–ubiquitin conjugates were captured by immobi-
lized metal affinity chromatography (IMAC). Ni-NTA Agarose
beads (Qiagen) were incubated in cell lysates for 2 h at RT and
washed five times in 8 M urea. Proteins conjugates wereplasmid for HA-ELK-1 and either empty vector (LH panel) or expression vector
0, 4, 8, 12, 16, and 20 h. Cell were lysed and equal amounts of protein were reso
indicated. Lower panel shows densitometric quantification of the results using
experiments n = 3. Significance was evaluated by Student’s t-test. A significantreleased from the beads in SDS gel-loading buffer containing
200 mM imidazole, resolved by SDS-PAGE, and detected by
immunoblotting.
Protein turnover assays
HEK293T cells were transfected with vectors for ELK-1 and
FBXO25 or control vector. Forty hours posttransfection, cells
were treated with the translation inhibitor cycloheximide
(CHX) at a concentration of 200 μM for 4 to 20 h. Samples
were lysed in RIPA buffer, normalized for protein concentra-
tion, and ELK-1 protein levels were analyzed by SDS-PAGE
and immunoblotting.
Protein mass spectrometry
HEK293T cells were transfected with a vector encoding His-
tagged Hand1 and harvested after 48 h. IMAC-enriched
Hand1 was resolved by SDS-PAGE, excised from the gel,
reduced, alkylated, and digested with trypsin. Peptides were
submitted to tandem mass spectrometry (MS/MS) on an LTQ-
Orbitrap spectrometer with nanoflow liquid chromatography
(LC). Identification of peptides was conducted in data-
dependent mode, utilizing Scaffold (4.11.1) software to assign
peaks using the Mascot (2.7.0) search engine, with raw data
files run against the human Uniprot database (2018), cRAP
database (2019), and a custom Hand1-His sequence (93,735
proteins, 2 max missed cleavages, precursor ion mass tolerance
20 PPM, fragment ion mass tolerance 0.100 Da, peptide
threshold 95% minimum, peptide false discovery rate 0.4%).
Carbamidomethyl (+57 on C) was considered a fixed modifi-
cation, while deamidation (+1 on NQ), oxidation (+16 on M),
phosphorylation (+80 on STY), and ubiquitination (+114 on K)
were considered as variable modifications.
Gene expression assays
Quantitative RT-PCR analyses were performed as previously
described (26). Cells were homogenized and RNA purified
using the Nucleospin RNA Kit (Macherey-Nagel). RNA was
checked for quantity and quality using the Nanodrop 2000
(Thermo-Scientific) and RNA Nano BioAnalyzer chip (Agilent
Technologies). Total RNA (1000 ng) was enriched for mRNA
using Dynabeads mRNA Purification Kit (Ambion by Life
Technologies) prior to cDNA synthesis. For cDNA synthesis,
500 ng of total RNA or mRNA eluted from Dynabeads was
reverse transcribed using AffinityScript reverse transcriptase
(Agilent Technologies) in a total reaction volume of 23 μl.
Reactions were incubated at 25 C for 10 min, 50 C for
60 min, and 70 C for 15 min to terminate the reaction. Gene
expression was quantified using the relative standard curvefor FBXO25-V5 (RH panel). After 40 h cells were treated with 200 μM CHX for
lved by SDS-PAGE. Immunoblot analysis was performed with the antibodies
AIDA Image Analyzer software. ELK-1 levels were normalized to actin. For all
difference in turnover was detected only at the 16-h time point (p = 0.047).
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Figure 3. FBXO25 affects Hand1 ubiquitination and HAX1 stability in apoptotic cells. A, whole-cell extracts from HEK293T cells transfected with
expression vectors for ELK-1-His, HA-UBQ, Myc-FBXO25, and Myc-FBXO25ΔF, as indicated, were subjected to IMAC under denaturing conditions. Isolated
proteins were analyzed by SDS-PAGE and immunoblotting with the antibodies indicated. The result is representative of three independent experiments.
B, HEK293T cells transfected with expression vectors for ELK-1-His, HA-UBQ, Myc-FBXO25, and Myc-FBXO25ΔF, as indicated, were treated with MG132
(20 μM) for 6 h, then whole-cell extracts were prepared and subjected to IMAC under denaturing conditions. Isolated proteins were analyzed by SDS-PAGE
and immunoblotting with the antibodies indicated. The result is representative of three independent experiments. C, whole-cell extracts were prepared
from HEK293T cells transfected with expression vectors for ELK-1-His, Hand1-His, HA-UBQ, and Myc-FBXO25, as indicated, and subjected to IMAC under
denaturing conditions. Isolated proteins were separated by gradient SDS-PAGE and analyzed by immunoblotting with the antibodies indicated.
FBXO25 pseudo-substrate ELK-1
6 J. Biol. Chem. (2021) 296 100214
Figure 4. USP17 but not FBXO25 modulates ELK-1 ubiquitination and target genes. A, HEK293T cells were transfected with expression vector for
FBXO25 or vector control as indicated. After 48 h cells were untreated or stimulated with tetradecanoylphorbol acetate (TPA) for 1 h as indicated. Whole-cell
extracts were prepared and analyzed by SDS-PAGE and immunoblotting for FBXO25 expression and ERK phosphorylation as indicated. B, RNA was prepared
from cells treated as in (A) and CFOS and EGR1 mRNA were analyzed by qRT-PCR. Levels are presented as fold ratios to GAPDH (n = 3). Error bars show SEM.
C, HEK293T cells were transfected with expression vectors for ELK-1-His, HA-UBQ, USP7 (WT and C > S mutant), or Myc-USP17 (WT and C > S mutant), as
indicated. Whole-cell extracts were prepared and subjected to IMAC under denaturing conditions. Isolated proteins were separated by gradient SDS-PAGE
and analyzed by immunoblotting with the antibodies indicated. This experiment was performed twice. D, RNA was prepared from cells treated as in (C) and
CFOS mRNA was analyzed by qRT-PCR. Levels are presented as fold ratios to GAPDH (n = 3). Error bars show SEM.
D, densitometric quantification of ELK-1 and Hand1 ubiquitination as a function of FBXO25 expression, as shown in (C) (n = 3: *p < 0.05 [0.0395], Student’s
t-test). E, whole-cell extracts were prepared from HeLa cells transfected with expression vectors for ELK-1-His, Hand1-His, HA-UBQ, and FBXO25, as indicated,
and subjected to IMAC under denaturing conditions. Isolated proteins were separated by gradient SDS-PAGE and analyzed by immunoblotting with the
antibodies indicated. This experiment was performed twice. F, amino acid sequence of murine Hand1 (Q64279.1) with bHLH domain highlighted in yellow,
K163 in red and phosphorylation sites T107, S109, and S112 in blue. Underscores denote peptide sequence coverage. The histogram below indicates total
spectral counts for K163-containing Hand1 peptides and K48-containing ubiquitin peptides with diglycine remnants (+114). The data are from two ex-
periments. G, MEFs were transfected with vectors for FBXO25 and FBXO25ΔF or vector control as indicated. Cells were untreated or treated 48 h post-
transfection with etoposide for 24 h as indicated. Levels of endogenous HAX-1, ELK-1, PARP cleavage and ectopically expressed FBXO25 were determined
by SDS-PAGE and immunoblotting. H, quantification of HAX-1 protein levels (n = 3; *p < 0.05 [0.034], Student’s t-test).
FBXO25 pseudo-substrate ELK-1
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Figure 5. Depletion of USP17 but not FBXO25 modulates ELK-1 ubiquitination and target genes. A, whole cell lysates were prepared from
untransfected HEK293T cells and cells transfected with expression vector for FBXO25. Protein concentrations were determined and lysates were mixed at
different ratios to titrate out ectopically expressed FBXO25, as indicated. Proteins mixtures were separated by SDS-PAGE and analyzed by immunoblotting
with the antibodies indicated. Signals corresponding to exogenous and endogenous FBXO25 are indicated. B, whole-cell lysates were prepared from
HEK293T cells transfected with shFBXO25#1 and shFBXO25#2 or vector control, as indicated, and FBXO25 levels were determined by SDS-PAGE and
immunoblotting. C, whole-cell extracts were prepared from HEK293T cells transfected with expression vectors for ELK-1-His, HA-UBQ, shFBXO25#1,
shFBXO25#2, or vector control (pSuper) and subjected to IMAC under denaturing conditions. Isolated proteins were analyzed by SDS-PAGE and immu-
noblotting with the antibodies indicated. The result is representative of two independent experiments. D, RNA was prepared from cells treated as in (C) and
CFOS and EGR1 mRNA were analyzed by qRT-PCR. Levels are presented as fold ratios to GAPDH (n = 4). Error bars show SEM. E, whole-cell extracts were
prepared from HEK293T cells transfected with expression vectors for ELK-1-His, HA-UBQ, shUSP17, or vector control, as indicated, and subjected to IMAC
under denaturing conditions. Isolated proteins were analyzed by SDS-PAGE and immunoblotting with the antibodies indicated. The result is representative
of two independent experiments. F, RNA was prepared from cells treated as in (E) and CFOS and EGR1 mRNA were analyzed by qRT-PCR. Levels are
presented as fold ratios to GAPDH (n = 4; *p < 0.05 [both 0.019], Student’s t-test).
FBXO25 pseudo-substrate ELK-1method. Primers and probes were designed using Primer Ex-
press Software and synthesized by Eurofins Genomics (Ger-
many). Gene-specific primers and probes are listed in the
Supplementary Information.8 J. Biol. Chem. (2021) 296 100214Densitometry and statistical analysis
Densitometry was performed using Image J or AIDA soft-
ware. Densitometry and qRT-PCR data are presented as
mean ± SEM. Statistical analyses were performed with
FBXO25 pseudo-substrate ELK-1Student’s t-test. Significance is reported in figures by *p < 0.05,
**p < 0.01.
Data availability
The mass spectrometry proteomics data have been depos-
ited with the ProteomeXchange Consortium via the PRIDE
partner repository under the data set identifier PXD022407
and 10.6019/PXD022407. Hand1 (and ubiquitin) peptides are
tabulated in Supplementary Information. All other relevant
data are contained within the article. Further information on
plasmids is available upon request.
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